GlaxoSmithKline has struck a backloaded $481 million deal with Sosei Heptares to secure the rights to a potential therapy for inflammatory bowel disease (IBD) and related conditions. The agreement gives GSK global rights to a portfolio of GPR35 agonists discovered by Sosei.

Agios Pharmaceuticals’ roots are in cancer drug development, but it’s passing that baton to Servier as it doubles down on its programs in genetically defined diseases, including a drug it’s developing for noncancerous blood diseases. The deal will see $1.8 billion changing hands upfront, but the deal could reach $2 billion in value if vorasidenib, a clinical-stage asset, hits certain goals.

Patrick Soon-Shiong’s NantKwest made a splash in 2015 with its $207 million IPO, but five years on, it’s becoming the vehicle for fellow Nant company ImmunityBio to go public.

Roche’s VEGFxAng2 bispecific antibody faricimab has matched Regeneron’s blockbuster Eylea in two phase 3 diabetic macular edema clinical trials. Faricimab was non-inferior to Eylea despite people on the experimental drug transitioning to a 16-week dosing window during the study.

San Diego-based Janux Therapeutics forged a strategic collaboration with pharma giant Merck potentially worth more than $1 billion to develop next-generation T cell engager immunotherapies for the treatment of cancer.

San Diego biotech Janux Therapeutics has penned a major biobucks R&D pact focused on next generation T-cell engager immunotherapies in cancer.

Philips aims to broaden the reach of its digital patient monitoring platforms, from inside the hospital out to the home, through a $2.8 billion acquisition deal for BioTelemetry and its wearable heart-tracking devices.

Mereo BioPharma is teaming up with Ultragenyx to work on its rare genetic bone disease drug.

Penny stock biotech Seneca Biopharma has found a lifeline in privately owned Leading BioSciences as it merges with the biotech.

The Nasdaq has been a hopping place this year, with new biotechs adding their symbol to the ticker every week and others flooding the market with more stock. Every time positive trial data is reported or a nod from the FDA comes through, stock prices soar.